BIOA (Bioage Labs) Ending Cash Position : $334.47 Mil (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Bioage Labs Ending Cash Position?

Bioage Labs's Ending Cash Position for the quarter that ended in Sep. 2024 was $334.47 Mil.

Bioage Labs's quarterly Ending Cash Position declined from Mar. 2024 ($177.31 Mil) to Jun. 2024 ($159.09 Mil) but then increased from Jun. 2024 ($159.09 Mil) to Sep. 2024 ($334.47 Mil).

Bioage Labs's annual Ending Cash Position increased from . 20 ($0.00 Mil) to Dec. 2022 ($27.64 Mil) but then declined from Dec. 2022 ($27.64 Mil) to Dec. 2023 ($24.96 Mil).

Bioage Labs Ending Cash Position Historical Data

The historical data trend for Bioage Labs's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioage Labs Ending Cash Position Chart

Bioage Labs Annual Data

Trend

Dec22

Dec23

Ending Cash Position

27.64

24.96

Bioage Labs Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Ending Cash Position	Get a 7-Day Free Trial			34.53	24.96	177.31	159.09	334.47

Bioage Labs Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Bioage Labs's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	27.644	+	-2.687
	=	24.96

Bioage Labs's Ending Cash Position for the quarter that ended in Sep. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	159.085	+	175.389
	=	334.47

Bioage Labs Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Bioage Labs's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioage Labs Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bioage Labs Inc (NAS:BIOA) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

1445A South 50th Street, Richmond, CA, USA, 94804

Website

https://www.bioagelabs.com

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.